These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 20510884)
1. Glioma-derived mutations in IDH: from mechanism to potential therapy. Fu Y; Huang R; Du J; Yang R; An N; Liang A Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884 [TBL] [Abstract][Full Text] [Related]
2. IDH mutations in glioma and acute myeloid leukemia. Dang L; Jin S; Su SM Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206 [TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Weller M; Wick W; von Deimling A Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161 [TBL] [Abstract][Full Text] [Related]
4. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy. Fu Y; Huang R; Zheng Y; Zhang Z; Liang A Biochem Biophys Res Commun; 2011 Jul; 410(2):218-23. PubMed ID: 21641335 [TBL] [Abstract][Full Text] [Related]
5. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337 [TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Zhu J; Zuo J; Xu Q; Wang X; Wang Z; Zhou D Med Hypotheses; 2011 Apr; 76(4):602-3. PubMed ID: 21284999 [TBL] [Abstract][Full Text] [Related]
7. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance. Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944 [TBL] [Abstract][Full Text] [Related]
8. IDH1 mutations in gliomas: when an enzyme loses its grip. Frezza C; Tennant DA; Gottlieb E Cancer Cell; 2010 Jan; 17(1):7-9. PubMed ID: 20129244 [TBL] [Abstract][Full Text] [Related]
9. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614 [TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Agnihotri S; Aldape KD; Zadeh G Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382 [TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. Han CH; Batchelor TT Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010 [TBL] [Abstract][Full Text] [Related]
12. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503 [TBL] [Abstract][Full Text] [Related]
13. IDH1 and IDH2 mutations in gliomas. Ducray F; Marie Y; Sanson M N Engl J Med; 2009 May; 360(21):2248-9; author reply 2249. PubMed ID: 19469031 [No Abstract] [Full Text] [Related]
14. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336 [TBL] [Abstract][Full Text] [Related]
15. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224 [TBL] [Abstract][Full Text] [Related]
16. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018 [TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923 [TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance metabolic imaging of glioma. Metellus P; Figarella-Branger D Sci Transl Med; 2012 Jan; 4(116):116ps1. PubMed ID: 22238331 [TBL] [Abstract][Full Text] [Related]
20. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis. Ohba S; Hirose Y Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]